A Trojan horse for thirsty tumours
Elie Dolgin • July 11, 2024
Joining a drug candidate to a protein that malignant cells naturally take up allowed one firm to come up with a potent anti-cancer therapy.
Read at Nature Outlook.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.